This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress
by Sweta Jaiswal, FRM
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.
What Lies Ahead for Healthcare ETFs in Q4 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Healthcare ETFs in Focus on UnitedHealth's Q4 Earnings
by Sweta Killa
UnitedHealth Group reported mixed fourth-quarter 2019 results wherein it breezed past the Zacks Consensus Estimate on earnings but lagged on revenues.
Deal or No Deal: Healthcare ETFs to Make a Sweep in 2020
by Sanghamitra Saha
While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Healthcare ETFs to Buy on UnitedHealth's Solid Q3 Earnings
by Sweta Killa
Investors could tap the company's strong growth story with ETFs having the largest allocation to this health insurance giant.
JNJ Beats, Ups View: Healthcare ETFs to Buy
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Healthcare ETFs in Focus on UnitedHealth's Q2 Earnings
by Sweta Killa
ETFs having the largest allocation to this health insurance giant are in focus post Q2 earnings.
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
by Sweta Killa
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Forget Trade Fears, Invest in Defensive Sector ETFs
by Sweta Killa
Investors are seeking to beat the fresh tariff woes by betting on defensive sectors like utilities, real estate, healthcare and consumer staples. We have highlighted one ETF each from these four zones.
Can Q1 Earnings Lift Healthcare ETFs Higher?
by Sweta Killa
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
UnitedHealth Falls Despite Q1 Beat, Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth Group reported robust first-quarter 2019 results. The company breezed past the Zacks Consensus Estimate on both earnings and revenues and raised its full-year forecast.
JNJ Beats, Ups Sales Growth View: Healthcare ETFs in Focus
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and also outpaced revenue estimates. Though it raised the guidance for full-year sales growth, it tightened the earnings per share forecast.
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
Healthcare ETFs in Focus Ahead of Q4 Earnings
by Sweta Killa
With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.
JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus
by Sweta Killa
Johnson & Johnson expects its sales growth to slow down this year due to pricing pressures and generic-drug competition for its pharmaceutical division. This has put healthcare ETFs in focus.
UnitedHealth Pops on Solid Q4: Healthcare ETFs to Buy
by Sweta Killa
ETFs having the largest allocation to UnitedHealth has been in focus post its solid result.
10 Top-Ranked ETFs That Crushed the Market in 2018
by Sweta Killa
While there have been losers in most corner of the space, several ETFs still managed to end the year in green and are likely to continue outperforming in 2019 too.
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
3 Globally Winning ETF Areas of Q3
by Sanghamitra Saha
Inside the winning ETF areas of the third quarter.
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
Healthcare ETF (IYH) Hits New 52-Week High
by Sweta Killa
This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?
4 Sector ETFs to Tap at New Highs
by Sweta Killa
While there are winners in many corners of the stock market, investors should tap the sectors that are expected to continue moving higher in the weeks ahead.
Healthcare ETFs to Buy on Solid Q2 Earnings Expectations
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.